ALK and large cell neuroendocrine carcinoma: By comparison, ALK-rearranged NSCLC patients represent a similar sized lung cancer subgroup and have been the basis of pioneering international randomised phase 3 trials involving up to 343 patients.4–6 The main contrast between LCNEC and ALK subgroups is that the latter currently represents an easily identifiable subtype, readily diagnosed using small biopsies.